Rallybio Corporation is a clinical-stage biotech company focused on developing therapies for severe and rare diseases. Their pipeline targets unmet medical needs in maternal fetal health, complement dysregulation, hematology, and metabolic disorders. They have two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), and RLYB116, a complement component 5 (C5) inhibitor for treating complement dysregulation diseases. Other candidates include RLYB114, a C5-targeted molecule for ophthalmic diseases, RLYB331 for severe anemia, and the ENPP1 program. We show 15 historical shares outstanding datapoints in our coverage of RLYB's shares outstanding history.
Understanding the changing numbers of RLYB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RLYB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RLYB by allowing them to research RLYB shares outstanding history
as well as any other stock in our coverage universe. |
Free RLYB Email Alerts:
Video: Shares Outstanding Importance
